NVO ▲ +0.2% - Novo Nordisk A/S
$NVO - Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
06-NOV-2026 03:08 PM ET
Share this post
More filings for $NVO
NVO ▲ +3.3% - Novo Nordisk A/SNov 4, 2026NVO ▲ +1.1% - Novo Nordisk A/SOct 20, 2026NVO ▼ -1.2% - Novo Nordisk A/SSep 29, 2026NVO ▼ -0.3% - Novo Nordisk A/SSep 23, 2026NVO ▼ -4.8% - Novo Nordisk A/SSep 21, 2026NVO ▼ -5.2% - Novo Nordisk A/SSep 21, 2026
View full $NVO filing history →💬 Comments
Loading comments…
Leave a comment